THU0421 Secukinumab is Effective in Reducing Dactylitis and Enthesitis Using Multiple Measures in Patients with Psoriatic Arthritis: Data from a Phase 3 Randomized, Multicenter, Double-Blind, Placebo-Controlled Study (Future 2)

2015 ◽  
Vol 74 (Suppl 2) ◽  
pp. 351.1-351 ◽  
Author(s):  
B. Kirkham ◽  
I.B. McInnes ◽  
P. Mease ◽  
J. Kremer ◽  
S. Kandala ◽  
...  
Keyword(s):  
Psoriatic Arthritis ◽  
Controlled Study ◽  
Phase 3 ◽  
Double Blind ◽  
Double Blind Placebo ◽  
Multiple Measures ◽  
Future 2

scholarly journals Secukinumab, a human anti-interleukin-17A monoclonal antibody, in patients with psoriatic arthritis (FUTURE 2): a randomised, double-blind, placebo-controlled, phase 3 trial

The Lancet ◽  
2015 ◽  
Vol 386 (9999) ◽  
pp. 1137-1146 ◽  
Author(s):  
Iain B McInnes ◽  
Philip J Mease ◽  
Bruce Kirkham ◽  
Arthur Kavanaugh ◽  
Christopher T Ritchlin ◽  
...  
Keyword(s):  
Monoclonal Antibody ◽  
Psoriatic Arthritis ◽  
Phase 3 ◽  
Double Blind ◽  
Double Blind Placebo ◽  
Interleukin 17A ◽  
Future 2
Sign in / Sign up

Export Citation Format

Share Document